Satria Antaran Prima Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Satria Antaran Prima Tbk. trades at Rp505 (market cap 338.33B, 8.96M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Satria Antaran Prima Tbk. is far larger — about 3.2× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SAPX | SCPI | |
|---|---|---|
Market Cap | 338.33B | 104.4B |
Volume | 8.96M | — |
Lot | 89.58K | — |
Turnover | 4.43B | — |
Average Price | 494.82 | — |
Value | 4.43B | — |
Indicative Equilibrium Price | 505 | — |
Indicative Equilibrium Volume | 58 | — |
Trailing returns across standard periods
Latest headlines on both assets
PT Satria Antaran Prima Tbk (the Company) was established based on Notarial Deed No. 1 ofBambang Sularso, S.H., dated July 1, 2014, notary in Jakarta.
Read more on SAPX →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →